Pharvaris N.V. (NASDAQ:PHVS – Get Free Report) Director Johannes Gerardus Chri Schikan sold 200,000 shares of the business’s stock in a transaction that occurred on Thursday, September 17th. The shares were sold at an average price of $35.00, for a total value of $7,000,000.00. Following the transaction, the director owned 115,167 shares of the company’s stock, valued at approximately $4,030,845. This trade represents a 63.46% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.
Johannes Gerardus Chri Schikan also recently made the following trade(s):
- On Tuesday, June 30th, Johannes Gerardus Chri Schikan sold 30,712 shares of Pharvaris stock. The stock was sold at an average price of $35.49, for a total transaction of $1,089,968.88.
- On Monday, June 29th, Johannes Gerardus Chri Schikan sold 6,888 shares of Pharvaris stock. The shares were sold at an average price of $35.05, for a total transaction of $241,424.40.
Pharvaris Price Performance
PHVS opened at $33.07 on Thursday. The firm has a market cap of $2.16 billion, a P/E ratio of -10.84 and a beta of -2.33. Pharvaris N.V. has a 1-year low of $20.65 and a 1-year high of $43.25. The company has a 50 day simple moving average of $35.36 and a two-hundred day simple moving average of $31.93.
Analysts Set New Price Targets
Several analysts recently issued reports on the company. Rosenblatt Securities set a $60.00 target price on Pharvaris in a research report on Wednesday, September 9th. Leerink Partners upped their price target on Pharvaris from $50.00 to $65.00 and gave the stock an “outperform” rating in a research note on Wednesday, September 9th. Morgan Stanley lifted their price objective on shares of Pharvaris from $46.00 to $62.00 and gave the company an “overweight” rating in a research report on Wednesday, September 9th. HSBC raised shares of Pharvaris to an “overweight” rating in a report on Thursday, August 13th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Pharvaris in a research note on Friday, July 17th. Thirteen investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $59.87.
View Our Latest Analysis on Pharvaris
Institutional Investors Weigh In On Pharvaris
A number of hedge funds have recently bought and sold shares of the business. Quantbot Technologies LP purchased a new position in shares of Pharvaris in the 2nd quarter worth $41,000. CoreCap Advisors LLC bought a new stake in Pharvaris in the second quarter worth about $93,000. Public Employees Retirement System of Ohio purchased a new stake in shares of Pharvaris during the second quarter valued at $196,000. Algert Global LLC purchased a new position in Pharvaris in the 2nd quarter worth about $238,000. Finally, Persistent Asset Partners Ltd bought a new stake in Pharvaris during the 2nd quarter valued at about $273,000.
About Pharvaris
Pharvaris N.V. is a biopharmaceutical company focused on developing oral therapies for hereditary angioedema (HAE), a rare genetic disorder characterized by recurrent episodes of swelling. The company is headquartered in Zug, Switzerland, and was founded in 2015 by former executives from Pharming Group.
Pharvaris’ lead investigational medicine is deucrictibant, an orally administered small-molecule bradykinin B2 receptor antagonist. The company is evaluating different formulations of deucrictibant for both on-demand treatment of HAE attacks and long-term prevention of attacks.
Featured Articles
- Five stocks we like better than Pharvaris
- Chips to Bots: Qualcomm’s Agentic AI Breakout
- Ciena Fell 40%—Now One Analyst Sees 50% Upside
- Energy Transfer Taps the AI Power Boom
- Viking’s Obesity Edge May Be Staying Power, Not Weight Loss
Receive News & Ratings for Pharvaris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharvaris and related companies with MarketBeat.com's FREE daily email newsletter.
